MDT-AP-2299
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- sex
- M
- new_clusters
- C5
- umap1_2d
- 5.351366821
- umap2_2d
- 5.608223776
- umap1_3d
- 1.474829707
- umap2_3d
- 0.123892996
- umap3_3d
- -0.967998451
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.480
- PANCREAS_BETA_CELLS+0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- COAGULATION+0.340
- FATTY_ACID_METABOLISM+0.340
- XENOBIOTIC_METABOLISM+0.310
- COMPLEMENT+0.290
- INFLAMMATORY_RESPONSE+0.290
- ESTROGEN_RESPONSE_LATE+0.280
- KRAS_SIGNALING_DN+0.270
Top 10 suppressed
- MITOTIC_SPINDLE-0.470
- WNT_BETA_CATENIN_SIGNALING-0.440
- TGF_BETA_SIGNALING-0.390
- NOTCH_SIGNALING-0.270
- UV_RESPONSE_DN-0.260
- PI3K_AKT_MTOR_SIGNALING-0.230
- PROTEIN_SECRETION-0.210
- ANDROGEN_RESPONSE-0.180
- G2M_CHECKPOINT-0.150
- HEME_METABOLISM-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-5066-01A-01R-1628-07 | — | cohortA1 | 0.835 |
| 2 | TCGA-49-4506-01A-01R-1206-07 | — | cohortA4 | 0.827 |
| 3 | SRR1421305 | GTEX | — | 0.825 |
| 4 | TCGA-E9-A6HE-01A-11R-A31O-07 | — | B | 0.824 |
| 5 | MDT-AP-2183 | Med | Medulloblastoma | 0.819 |
| 6 | TCGA-OL-A66P-01A-11R-A31O-07 | — | B | 0.807 |
| 7 | MDT-AP-2389 | Med | Medulloblastoma | 0.791 |
| 8 | TCGA-33-4589-01A-01R-1443-07 | — | cohortSQ1 | 0.787 |
| 9 | TCGA-BH-A0AW-01A-11R-A056-07 | — | C | 0.783 |
| 10 | MDT-AP-2372 | Med | Medulloblastoma | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.460 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.310 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |